Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0O5TR
|
|||
Former ID |
DIB011031
|
|||
Drug Name |
RBP-7000
|
|||
Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 3 | [1] | |
Schizophrenia [ICD-11: 6A20] | Application submitted | [2] | ||
Company |
Reckitt benckiser pharmaceutical
|
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02109562) Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 3 | Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014 Jun;53(6):533-43. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.